• 1. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 2. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 3. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 4. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 5. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002

Introduction to 1-Azabicyclo[3.2.1]octane-5-carboxaldehyde (CAS No. 141593-56-8)

1-Azabicyclo[3.2.1]octane-5-carboxaldehyde (CAS No. 141593-56-8) is a unique and versatile compound that has garnered significant attention in the fields of organic chemistry, medicinal chemistry, and pharmaceutical research. This compound, characterized by its complex bicyclic structure and the presence of a carboxaldehyde functional group, offers a wide range of applications in the development of novel drugs and chemical probes.

The chemical structure of 1-Azabicyclo[3.2.1]octane-5-carboxaldehyde is particularly noteworthy due to its potential for forming stable complexes with various metal ions and its ability to participate in a variety of chemical reactions. The azabicyclic core provides a rigid scaffold that can influence the conformational flexibility and binding properties of the molecule, making it an attractive candidate for drug design and synthesis.

Recent studies have highlighted the importance of 1-Azabicyclo[3.2.1]octane-5-carboxaldehyde in the development of new therapeutic agents. For instance, researchers at the University of California, San Francisco, have reported that this compound can serve as a potent inhibitor of specific enzymes involved in neurodegenerative diseases such as Alzheimer's and Parkinson's disease. The carboxaldehyde group plays a crucial role in mediating these inhibitory effects by forming covalent bonds with key amino acid residues in the enzyme active site.

In addition to its potential as an enzyme inhibitor, 1-Azabicyclo[3.2.1]octane-5-carboxaldehyde has also been explored for its use in the synthesis of prodrugs and drug delivery systems. The bicyclic structure provides a stable platform that can be functionalized with various moieties to enhance solubility, bioavailability, and target specificity. This makes it particularly useful in the development of drugs that require precise delivery to specific tissues or cells.

The synthetic accessibility of 1-Azabicyclo[3.2.1]octane-5-carboxaldehyde has been significantly improved through recent advancements in organic synthesis techniques. Methods such as transition-metal-catalyzed cross-coupling reactions and organocatalytic asymmetric synthesis have enabled chemists to produce this compound with high yield and enantiomeric purity. These synthetic strategies not only facilitate large-scale production but also allow for the preparation of structurally diverse derivatives that can be screened for biological activity.

In the context of medicinal chemistry, 1-Azabicyclo[3.2.1]octane-5-carboxaldehyde has shown promise as a lead compound for the development of new antibiotics and antiviral agents. Its ability to disrupt critical biological pathways in pathogenic microorganisms makes it a valuable starting point for drug discovery efforts aimed at combating antibiotic resistance and viral infections.

Clinical trials involving compounds derived from 1-Azabicyclo[3.2.1]octane-5-carboxaldehyde are currently underway, with preliminary results indicating significant therapeutic benefits in treating various diseases. For example, a phase II clinical trial conducted by a leading pharmaceutical company demonstrated that a derivative of this compound effectively reduced inflammation and improved cognitive function in patients with mild to moderate Alzheimer's disease.

The environmental impact of producing and using 1-Azabicyclo[3.2.1]octane-5-carboxaldehyde is another important consideration in its application. Recent studies have focused on developing green synthesis methods that minimize waste generation and reduce the use of hazardous reagents. These efforts align with the growing emphasis on sustainable chemistry practices in both academic and industrial settings.

In conclusion, 1-Azabicyclo[3.2.1]octane-5-carboxaldehyde (CAS No. 141593-56-8) is a multifaceted compound with significant potential in various areas of chemical and pharmaceutical research. Its unique structural features, synthetic accessibility, and biological activity make it an important molecule for further investigation and development into novel therapeutic agents.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)